Biogen Amevive NDA Filing For Psoriasis Expected In Second Half Of 2001
Executive Summary
Biogen plans to file an NDA for the T-cell modulator Amevive for psoriasis in the second half of 2001, VP-Medical Research Burt Adelman, MD, said during the company's first quarter conference call April 12.
You may also be interested in...
Genentech Considers Xanelim Chronic Psoriasis Therapy Indication
Genentech hopes to position Xanelim for use as a chronic therapy for moderate to severe plaque psoriasis based on six-month data.
Genentech Considers Xanelim Chronic Psoriasis Therapy Indication
Genentech hopes to position Xanelim for use as a chronic therapy for moderate to severe plaque psoriasis based on six-month data.
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.